Thalidomide, which promotes TNF-α mRNA degradation and suppresses TNF-α production by monocytes, is reportedly effective in patients with intestinal BD and pediatric IBD (36–38), and in children with HA20 (39, 40). The gene discussed is TNF; the disease is A20 haploinsufficiency.